Weegink, Christine J.

Publishing since 2001 (Junior)

Has published 20 publications in 10 years

Number of publications published per year by Weegink, Christine J.. (Source : PubMed)

Distribution of publications types for Weegink, Christine J.. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

Takkenberg RB, Zaaijer HL, Menting S, Weegink CJ, Terpstra V, Cornelissen M, Dijkgraaf MG, Jansen PL, Reesink HW, Beld MG. Detection of hepatitis B virus covalently closed circular DNA in paraffin-embedded and cryo-preserved liver biopsies of chronic hepatitis B patients. Eur J Gastroenterol Hepatol 2010
Takkenberg RB, Weegink CJ, Zaaijer HL, Reesink HW. New developments in antiviral therapy for chronic hepatitis B. Vox Sang. 2009
Reesink HW, Weegink CJ. New hope for a cure for chronic hepatitis C. J. Hepatol. 2009;51;4
de Bruijne J, Weegink CJ, Jansen PL, Reesink HW. New developments in the antiviral treatment of hepatitis C. Vox Sang. 2009;97;1
Takkenberg RB, Zaaijer HL, Molenkamp R, Menting S, Terpstra V, Weegink CJ, Dijkgraaf MG, Jansen PL, Reesink HW, Beld MG. Validation of a sensitive and specific real-time PCR for detection and quantitation of hepatitis B virus covalently closed circular DNA in plasma of chronic hepatitis B patients. J. Med. Virol. 2009;81;6
Zaaijer HL, Takkenberg RB, Weegink CJ, Rebers SP, Menting S, Reesink HW, Schinkel J, Molenkamp R. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir. J. Med. Virol. 2009;81;3
Gelderblom HC, Zeuzem S, Weegink CJ, Forestier N, Mcnair L, Purdy S, Dijkgraaf MG, Jansen PL, Reesink HW. Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a. Scand. J. Gastroenterol. 2008;43;9
Gelderblom HC, Zaaijer HL, Dijkgraaf MG, Van Der Meer J, Weegink CJ, Jansen PL, Beld MG, Reesink HW. Prediction of virologic response in difficult-to-treat chronic hepatitis C patients during high-dose interferon induction therapy. Scand. J. Gastroenterol. 2008;43;7
Schreuder TC, Gelderblom HC, Weegink CJ, Hamann D, Reesink HW, Devries JH, Hoekstra JB, Jansen PL. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int. 2008;28;1
Kok A, Zuure FR, Weegink CJ, Coutinho RA, Prins M. [Hepatitis C in the Netherlands: sparse data on the current prevalence and the necessity for epidemiological studies and innovative methods for detecting infected individuals] Ned Tijdschr Geneeskd 2007;151;43

[ See timeline ] [ See all publications ]

h=11

means that Weegink, Christine J. has 11 papers cited a least 11 times - methodology

Key figures

20 pub in 10 years
2.0 publications/year
best year 2009 with 5 pub
h-index 11 with 20 pub
h-ratio : 55 %

See Timeline

Ranking

It's me !

Click here if you are
Weegink, Christine J..

Most frequent Journals

Eur J Gastroenterol Hepatol (3x)
Scand. J. Gastroenterol. (3x)
J. Hepatol. (2x)
Ned Tijdschr Geneeskd (2x)
J. Med. Virol. (2x)

Main affiliation

aDepartment of Gastroenterology and Hepatology, AMC Liver CenterbDepartment of PathologycLaboratory of Experimental Virology, Department of Medical MicrobiologydDepartment of Clinical Epidemiology and BiostatisticseMedical Microbiology and Karl Landsteiner Laboratory, Academic Medical Center, Center for Infectious Disease and Immunology (CINIMA), University of AmsterdamfRoyal Tropical Institute, KIT biomedical Research, Amsterdam, The Netherlands.

Latest co-workers

Beld MG Chamuleau RA Chu HM Cooreman MC Dijkgraaf MG Forestier N Gelderblom HC Jansen PL McNair L Menting S Molenkamp R Prins M Purdy S Reesink HW Sentjens RE Takkenberg RB Terpstra V Zaaijer HL Zeuzem S de Bruijne J

Back to HepaTop

Due mainly to homonyms, errors are possible and if you detect "false positives" or "false negatives" don't be too frustrated and please contact the webmaster.